RNA
Atrium Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.73 / 10
Netural
Analyst sentiment is mixed: a single Buy rating from Wells Fargo contrasts with a pessimistic market outlook and an 11% price decline. Fund‑flow metrics are solid (7.45), driven by strong small‑, medium‑ and large‑cap inflows, though overall trend is negative.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-11
InstitutionWells Fargo
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for RNA?
- RNA holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.73/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
